Abstract
Three histamine H2-receptor antagonists, Cimetidine, Metiamide and Ranitidine, were tested for their inhibitory effect on two experimental bowel cancer models. In the first model mitotic rates were measured in dimethylhydrazine-induced tumors of rat colon and in the second model volumetric changes in human large bowel cancer xenografts were assessed. In tumors of rat colon all three drugs were able to suppress mitotic activity, but the effects of Metiamide and Ranitidine were more prolonged than that of Cimetidine in each of two lines of human bowel cancer that were used. Metiamide and Ranitidine were also more effective growth inhibitors than was Cimetidine.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Cell Division / drug effects
-
Cimetidine / therapeutic use*
-
Colonic Neoplasms / chemically induced
-
Colonic Neoplasms / drug therapy*
-
Dimethylhydrazines
-
Female
-
Furans / therapeutic use*
-
Guanidines / therapeutic use*
-
Histamine H2 Antagonists / therapeutic use*
-
Humans
-
Male
-
Metiamide / therapeutic use*
-
Mice
-
Mice, Inbred CBA
-
Neoplasm Transplantation
-
Neoplasms, Experimental / chemically induced
-
Neoplasms, Experimental / drug therapy
-
Ranitidine
-
Rats
-
Rats, Inbred Strains
-
Thiourea / analogs & derivatives*
Substances
-
Dimethylhydrazines
-
Furans
-
Guanidines
-
Histamine H2 Antagonists
-
Metiamide
-
Cimetidine
-
Ranitidine
-
Thiourea